Lacosamide

Drug Profile

Lacosamide

Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒ

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator University of Houston
  • Developer Daiichi Sankyo Company; UCB
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine NMDA-associated antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase III Generalised seizures; Tonic-clonic epilepsy
  • Preclinical Pain
  • No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Sleep disorders
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 20 Dec 2016 Registered for Partial epilepsies (Monotherapy) in European Union, Liechtenstein, Iceland, Norway (PO)
  • 28 Nov 2016 UCB Pharma initiates a phase I trial in Healthy Japanese volunteers in United Kingdom (PO, Dry syrup) (NCT02972125)
  • 11 Nov 2016 Committee for Medicinal Products for Human Use (CHMP) recommends approval of lacosamide for Partial seizures (Monotherapy) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top